IO BIOTECH INC. - COM

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

13 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

10 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

08 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

01 Nov 2023 08:30:00 By Nasdaq GlobeNewswire

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress

23 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

03 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

12 Sep 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Participation in Upcoming Investor Conferences

06 Sep 2023 08:35:00 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 Second Quarter Results

11 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

IO Biotech Appoints Heidi Hunter to its Board of Directors

11 Aug 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

08 Aug 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech, Inc. Announces $75 Million Private Placement Financing

07 Aug 2023 08:30:12 By Nasdaq GlobeNewswire

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

28 Jul 2023 08:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

25 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

18 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

14 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

01 Jun 2023 08:30:00 By Nasdaq GlobeNewswire

IO Biotech to Present at the Jefferies Healthcare Conference

30 May 2023 16:35:00 By Nasdaq GlobeNewswire

IO Biotech Announces 2023 First-Quarter Results

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

14 Mar 2023 16:11:47 By Nasdaq GlobeNewswire